Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drugs In Development, 2021

Published: June 30, 2021 |

Global Markets Direct | 61 Pages | Delivery time: 1-2 business days

Price

Description
Table of Contents
List of Tables

Add to Compare

Summary:

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Human Cytomegalovirus envelope glycoprotein B plays an important role in host cell entry and cell to cell virus transmission. It is involved in the initial attachment via binding to heparan sulfate together with the gM/gN complex that binds heparin with higher affinity. It interacts with host integrin ITGB1, PDGFRA and EGFR that likely serve as post attachment entry receptors. It participates in the fusion of viral and cellular membranes leading to virus entry into the host cell.

Human Cytomegalovirus Envelope Glycoprotein B (gB) pipeline Target constitutes close to 10 molecules. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 6 and 1 respectively. Report covers products from therapy areas Infectious Disease, Oncology and Women's Health which include indications Cytomegalovirus (HHV-5) Infections, Chlamydia Infections, Ebolavirus Infections (Ebola Hemorrhagic Fever), Female Contraception, Gonorrhea, Human Immunodeficiency Virus (HIV) Infections (AIDS), Medulloblastoma, Recurrent Glioblastoma Multiforme (GBM), Simplexvirus (HSV) Infections and Trichomonas Vaginitis.

The latest report Human Cytomegalovirus Envelope Glycoprotein B - Drugs In Development, 2021, outlays comprehensive information on the Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

The report provides a snapshot of the global therapeutic landscape for Human Cytomegalovirus Envelope Glycoprotein B (gB)
The report reviews Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics and enlists all their major and minor projects
The report assesses Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics

Reasons to Buy:

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Human Cytomegalovirus Envelope Glycoprotein B (gB)Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Human Cytomegalovirus Envelope Glycoprotein B (gB) development landscape
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Product Code: GMDHC2842TDB

Introduction
Global Markets Direct Report Coverage
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Overview
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Companies Involved in Therapeutics Development
AlphaVax Inc
Citranvi Biosciences LLC
Helocyte Biosciences Inc
Merck & Co Inc
Stadius Biopharma LLC
Trellis Bioscience Inc
VBI Vaccines Inc
Yaso Therapeutics Inc
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drug Profiles
AVX-601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bi-specific Monoclonal Antibody to Target CD3 and Glycoprotein B for Cytomegalovirus (HHV-5) Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cytomegalovirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cytomegalovirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cytomegalovirus vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit gH and gB for Cytomegalovirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PPCM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRL-345 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBI-1501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBI-1901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Dormant Products
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Discontinued Products
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Product Development Milestones
Featured News & Press Releases
Jun 08, 2021: VBI Vaccines granted FDA fast track designation for VBI-1901 for the treatment of recurrent GBM
May 20, 2021: VBI Vaccines to present updated phase 2a tumor response and overall survival data for VBI-1901 in Recurrent GBM at 2021 ASCO Annual Meeting
Nov 19, 2020: VBI Vaccines announces positive interim Phase 2a data from VBI-1901 in recurrent GBM
Nov 09, 2020: VBI Vaccines announces e-poster presentation at the Society for Neuro-Oncology (SNO) 2020 Virtual Meeting
Sep 17, 2020: VBI Vaccines announces biomarker data from VBI-1901 phase 1/2a study in recurrent GBM presented at ESMO Virtual Congress 2020
Sep 14, 2020: VBI Vaccines to present additional biomarker data from VBI-1901 phase 1/2a study in recurrent GBM in an E-Poster at ESMO Virtual Congress 2020
Jun 22, 2020: VBI Vaccines announces data from VBI-1901 presented at AACR 2020: Partial response observed, promising biomarker strategy identified
May 15, 2020: VBI Vaccines announces upcoming poster presentation of Phase 1/2a data of VBI-1901 in Recurrent GBM Patients at AACR Virtual Annual Meeting
Mar 03, 2020: VBI Vaccines doses first recurrent GBM patient in trial of VBI-1901
Mar 03, 2020: VBI Vaccines provides update on part A of ongoing Phase 1/2a study demonstrating overall survival benefit for VBI-1901 vaccine responders in recurrent GBM patients
Nov 22, 2019: VBI Vaccines presents early GBM tumor response and immunologic data from part B of ongoing phase 1/2a study of VBI-1901 at the 2019 SNO Annual Meeting
Nov 11, 2019: VBI Vaccines to present initial phase 1/2a part B data of VBI-1901 at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting
Oct 24, 2019: VBI Vaccines to present new immuno-oncology data at the World Vaccine Congress Europe 2019
Sep 11, 2019: VBI to study cancer vaccine with GSK's adjuvant system
Jul 29, 2019: VBI Vaccines announces dosing of first recurrent GBM patient in Part B of ongoing phase 1/2a study of VBI-1901
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer